Paltusotine
Product Specifications
UNSPSC Description
Paltusotine (CRN00808) is an orally active, nonpeptide selective somatostatin type 2 (SST2) receptor agonist. Paltusotine has the potential for maintaining GH and IGF-1 levels after depot somatostatin receptor ligand therapy.Paltusotine can be used in research on acromegaly and neuroendocrine tumors[1][2][3].
Target Antigen
Somatostatin Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein;Neuronal Signaling
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Endocrinology; Cancer
Assay Protocol
https://www.medchemexpress.com/paltusotine.html
Purity
99.52
Solubility
DMSO : 10 mg/mL (ultrasonic;warming;heat to 60°C)
Smiles
N#CC1=CC=CC(C2=CC=C3N=CC(C4=CC(F)=CC(F)=C4)=C(N5CCC(N)CC5)C3=C2)=C1O
Molecular Weight
456.49
References & Citations
[1]Murray B. Gordon, et al. Identification of a dose range for once daily oral paltusotine in patients with acromegaly that maintains IGF-1 levels when switching from long-acting somatostatin receptor ligand therapy. Endocrine Abstracts (2021) 73 OC15.4.|[2]Rosa Luo, et al. Pharmacokinetics and Safety of an Improved Oral Formulation of Paltusotine, a Selective, Non-Peptide Somatostatin Receptor 2 (SST2) Agonist for the Treatment of Acromegaly. Journal of the Endocrine Society, Volume 5, Issue Supplement_1, April-May 2021.|[3]Zhao J, et al. Discovery of Paltusotine (CRN00808), a Potent, Selective, and Orally Bioavailable Non-peptide SST2 Agonist. ACS Med Chem Lett. 2022 Dec 10;14(1):66-74.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-109155/Paltusotine-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-109155/Paltusotine-SDS-MedChemExpress.pdf
Clinical Information
Phase 3
CAS Number
2172870-89-0
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items